The Pharma Sites
Cutting-edge production cycles that respect the Environment and improve Workplace Safety
The contrast media that are exported all over the world are produced and packaged in the Pharma production sites of Singen, Germany (BIPSO GmbH), Shanghai, China (Bracco SINE Pharmaceutical) and Montréal, Canada (E-Z-EM). In particular, non ionic contrast media are produced in Singen and Shanghai, whereas the Montréal site specialises in producing barium sulphate contrast media.
Singen (Baden Württemberg), Germany
|Number of employees||401|
|HSE investments (mln. €)||0.141|
|HSE costs (mln. €)||0.88|
|Total investments (mln. €)||60|
The BIPSO GmbH plant, situated in the Industrial Park of Singen, was purchased in May 2011 and is the Bracco Group’s largest sterile drug production plant. Bipso GmbH produces high-quality diagnostic imaging agents, which are exported to over 90 countries. The plant also produces sterile agents for other pharmaceutical companies on a contractual basis.
Total production, expressed in thousands of litres of prepared solution, decreased, compared with 2016, by 6.6%; specifically, production on behalf of third parties dropped by over 60%, whereas Bracco production decreased by 4.9%.
BRACCO SINE PHARMACEUTICAL CORP. LTD
|Number of employees||71 + 278 off-site*|
|HSE investments (mln. €)||-|
|HSE costs (mln. €)||0.039|
|Total investments (mln. €)||0.040|
The Bracco Sine industrial plant, situated in the Pudong area near Shanghai, has been operating since 2004 and is a highly technological facility with specialised equipment and services for the production of contrast media. Today the plant produces non-ionic contrast media for x-ray examinations, magnetic resonance imaging and ultrasound scans. Bracco Sine manages the entire production cycle on the basis of the Active Pharmaceutical Ingredient production process adopted by the Bracco plants in Italy. The site also repackages Bracco products destined for release on the Asian market.
Production (expressed as the number of pieces produced and including repackaging) increased by 21.6% in 2017 compared with the previous year.
* The off-site personnel are employees that work away from the production site (commercial and Shanghai offices)
E-Z-EM CANADA INC.
|Number of employees||175 + 10 off-site*|
|HSE investments (mln. €)||0.152|
|HSE costs (mln. €)||0.128|
|Total investments (mln. €)||1.3|
The E-Z-EM site in Montréal has been active since 1998 and was expanded in 2000 and 2004. The plant has been certified by the Canadian, United States and European health authorities (Health Canada, FDA, EMEA) for production and marketing activities. The contrast media produced in Canada, based on barium sulphate, are exported all over the world.
Production (expressed in millions of pieces) declined slightly in 2017 compared with the previous year (-0.4%). It should be noted that in the period 2015-2017, production for third parties was phased out and because of the different types of BaSO4 products being manufactured, the number of pieces produced may not always reflect impact, although it is the only available figure.
* The off-site personnel are employees that work away from the production site (Commercial)